Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL289247 | 0.84 | LOXL2 (0.57) | MAPTKDM4ECYP3A4LMNAMEN1 | |
| SCHEMBL198641 | 0.76 | MAPT (0.64) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL217044 | 0.75 | MAPT (1.00) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL8384663 | 0.74 | MAPT (0.61) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL3817705 | 0.74 | MAPT (0.54) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL3246068 | 0.73 | MAPT (0.58) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL610758 | 0.73 | MAPT (0.58) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL196873 | 0.73 | MAPT (0.58) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL566334 | 0.73 | MAPT (0.58) | MAPTKDM4EPOLBCYP3A4LMNA | |
| SCHEMBL428159 | 0.73 | MAPT (0.58) | MAPTKDM4EPOLBCYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024120467-A1 | PHOSPHORAMIDATE MONOSACCHARIDES, PHARMACEUTICAL COMPOSITIONS, AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | SURIO THERAPEUTICS CO. LTD (CN) | 2024-06-13 | — | — | WO | claimed |
| EP-3542801-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-09-25 | — | — | EP | claimed |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | claimed |
| EP-1912948-B1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-09 | — | — | EP | claimed |
| CN-101273016-B | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA NV | 2013-01-02 | — | — | CN | claimed |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | claimed |
| US-7915292-B2 | 2-{benzyl-[(6-methyl-2-phenyl-quinolin-3-yl)-phenyl-methyl]-amino}-N-(4-methyl-piperazin-1-yl)-acetamide; tuberculosis; antimycobacterial drugs; a tertiary nitrogen atom in the alpha position in the side chain attached to the 3-position of the quinoline nucleus to get fewer enantiomers possible | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-29 | — | — | US | claimed |
| CN-101784278-A | Purin derivatives for use in the treatment of FAB-related diseases | BOEHRINGER INGELHEIM INT | 2010-07-21 | — | — | CN | claimed |
| EP-2190434-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2010-06-02 | — | — | EP | claimed |
| EP-2091929-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | The European Molecular Biology Laboratory (DE) | 2009-08-26 | — | — | EP | claimed |
| CN-101421257-A | Agents that disrupt cellular replication and their use in inhibiting pathological conditions | EUROPEAN MOLECULAR BIOLOGY LAB EMBL (DE) | 2009-04-29 | — | — | CN | claimed |
| WO-2009024542-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-26 | — | — | WO | claimed |
| CN-101273016-A | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | CN | claimed |
| US-20080182855-A1 | Antibacterial Quinoline Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-31 | — | — | US | claimed |
| EP-1912948-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-23 | — | — | EP | claimed |
| WO-2007107352-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2007-09-27 | — | — | WO | claimed |
| WO-2007014885-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-08 | — | — | WO | claimed |
| US-4698329-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1987-10-06 | — | — | US | claimed |
| EP-0152255-A2 | New renin-inhibitory peptides and their use | SANKYO COMPANY LIMITED (JP) | 1985-08-21 | — | — | EP | claimed |
| WO-2024120467-A1 | PHOSPHORAMIDATE MONOSACCHARIDES, PHARMACEUTICAL COMPOSITIONS, AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | SURIO THERAPEUTICS CO. LTD (CN) | 2024-06-13 | — | — | WO | disclosed |
| EP-4261830-A1 | NOVEL PEPTIDOMIMETIC COMPOUND AND DESIGN | Oita University Institute of Advanced Medicine, Inc. (JP) | 2023-10-18 | — | — | EP | disclosed |
| CN-116615423-A | Novel peptidomimetic compounds and design | 株式会社大分大学先端医学研究所 | 2023-08-18 | — | — | CN | disclosed |
| US-20230165252-A1 | ACTIVE COMPOUND COMBINATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-01 | — | — | US | disclosed |
| US-20230054449-A1 | PYRIDAZINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-23 | — | — | US | disclosed |
| CN-111771885-B | Pest control composition comprising novel iminopyridine derivatives | 株式会社MMAG | 2022-05-17 | — | — | CN | disclosed |
| CN-112244015-B | Pest control composition comprising novel iminopyridine derivatives | 株式会社MMAG | 2022-05-17 | — | — | CN | disclosed |
| US-20220000877-A1 | AQUEOUS COMPOSITION, IN PARTICULAR FOR TREATING MUCOSA AND/OR WOUNDS | B. BRAUN MELSUNGEN AG (DE) | 2022-01-06 | — | — | US | disclosed |
| US-20210401848-A1 | AQUEOUS COMPOSITION, IN PARTICULAR FOR TREATING MUCOSA AND/OR WOUNDS | B. BRAUN MELSUNGEN AG (DE) | 2021-12-30 | — | — | US | disclosed |
| EP-3887362-A1 | PYRIDAZINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | Bayer Aktiengesellschaft (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3886805-A1 | AQUEOUS COMPOSITION, IN PARTICULAR FOR TREATING MUCOSA AND/OR WOUNDS | B. Braun Melsungen AG (DE) | 2021-10-06 | — | — | EP | disclosed |
| EP-3886804-A1 | AQUEOUS COMPOSITION, IN PARTICULAR FOR TREATING MUCOSA AND/OR WOUNDS | B. Braun Melsungen AG (DE) | 2021-10-06 | — | — | EP | disclosed |
| CN-113347960-A | Aqueous composition, in particular for the treatment of mucous membranes and/or wounds | B.布劳恩梅尔松根股份公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-113271924-A | Aqueous composition, in particular for the treatment of mucous membranes and/or wounds | B.布劳恩梅尔松根股份公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-112244015-A | Pest control composition comprising novel iminopyridine derivatives | 明治制果药业株式会社 | 2021-01-22 | — | — | CN | disclosed |
| CN-108684667-B | Pest control composition comprising novel iminopyridine derivatives | 明治制果药业株式会社 | 2020-12-01 | — | — | CN | disclosed |
| CN-111771885-A | Pest control composition comprising novel iminopyridine derivatives | 明治制果药业株式会社 | 2020-10-16 | — | — | CN | disclosed |
| WO-2020109391-A1 | PYRIDAZINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-04 | — | — | WO | disclosed |
| EP-3542801-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-09-25 | — | — | EP | disclosed |
| CN-110256336-A | Nitogen-contained heterocycle derivant with 2- imino group and the pest control agent comprising it | 明治制果药业株式会社 | 2019-09-20 | — | — | CN | disclosed |
| US-10349655-B2 | Pest control composition including novel iminopyridine derivative | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2019-07-16 | — | — | US | disclosed |
| US-10280193-B2 | Isoxazolidine derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-05-07 | — | — | US | disclosed |
| EP-2190434-B1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2019-04-17 | — | — | EP | disclosed |
| CN-106359439-B | Nuisance including novel iminopyridine derivative prevents composition | 明治制果药业株式会社 | 2018-10-30 | — | — | CN | disclosed |
| CN-108684667-A | Nuisance including novel iminopyridine derivative prevents composition | 明治制果药业株式会社 | 2018-10-23 | — | — | CN | disclosed |
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20180066010-A1 | ISOXAZOLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-03-08 | — | — | US | disclosed |
| EP-2789607-B1 | PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2018-02-07 | — | — | EP | disclosed |
| US-9845337-B2 | Isoxazolidine derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-12-19 | — | — | US | disclosed |
| CN-107223123-A | BCL-XL inhibitory compound having low cell permeability and antibody drug conjugate including the same | 艾伯维公司 | 2017-09-29 | — | — | CN | disclosed |
| CN-107207553-A | BCL-XL-inhibitory compounds and antibody drug conjugates including the same | 艾伯维公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-105228985-B | 3, 4-dihydroisoquinolin-2 (1H) -yl compounds | 伊莱利利公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-104583212-B | pyrimidinone derivatives as antimalarial agents | 赛诺菲 | 2017-04-19 | — | — | CN | disclosed |
| CN-104478875-B | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | 麦迪韦逊科技有限公司 | 2017-04-12 | — | — | CN | disclosed |
| CN-106359439-A | Pest control composition comprising an iminopyridine derivative | 明治制果药业株式会社 | 2017-02-01 | — | — | CN | disclosed |
| US-20160340349-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| CN-103391945-B | Isoxazolidine derivant | 奇斯药制品公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-104125774-B | Pest control composition comprising iminopyridine derivatives | 明治制果药业株式会社 | 2016-09-28 | — | — | CN | disclosed |
| US-9447072-B2 | Pyridone derivative and pharmaceutical containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| CN-103987706-B | Pyridione derivatives and the medicine containing Pyridione derivatives | 科研制药株式会社 | 2016-06-29 | — | — | CN | disclosed |
| US-20160165888-A1 | PEST CONTROL COMPOSITION INCLUDING NOVEL IMINOPYRIDINE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168540-A1 | COMPOSITION FOR MAINTAINING PLATELET FUNCTION | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | disclosed |
| EP-3006029-A1 | COMPOSITION FOR MAINTAINING PLATELET FUNCTION | Kaken Pharmaceutical Co., Ltd. (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-9301525-B2 | Pest control composition including novel iminopyridine derivative | MEUI SEIKA PHARMA CO., LTD. (JP) | 2016-04-05 | — | — | US | disclosed |
| CN-105392482-A | Composition for maintaining platelet function | KAKEN PHARMA CO LTD | 2016-03-09 | — | — | CN | disclosed |
| EP-1912948-B1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-09 | — | — | EP | disclosed |
| US-20150166506-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2015-06-18 | — | — | US | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| US-20150057257-A1 | ISOXAZOLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-02-26 | — | — | US | disclosed |
| US-20150005347-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 2-IMINO GROUP AND PEST CONTROL AGENT INCLUDING THE SAME | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2015-01-01 | — | — | US | disclosed |
| CN-104220424-A | Nitrogen-containing heterocyclic derivative having 2-imino group and pest control agent comprising the same | MEIJI SEIKA PHARMA CO LTD | 2014-12-17 | — | — | CN | disclosed |
| CN-104125774-A | Pest control composition comprising novel iminopyridine derivatives | MEIJI SEIKA PHARMA CO LTD | 2014-10-29 | — | — | CN | disclosed |
| US-20140315839-A1 | PEST CONTROL COMPOSITION INCLUDING NOVEL IMINOPYRIDINE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| EP-2789607-A1 | PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2014-10-15 | — | — | EP | disclosed |
| CN-103987706-A | Pyridone derivative and medicine containing same | KAKEN PHARMA CO LTD | 2014-08-13 | — | — | CN | disclosed |
| US-8802675-B2 | Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD (IL) | 2014-08-12 | — | — | US | disclosed |
| EP-2683371-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | Cereno Scientific AB (SE) | 2014-01-15 | — | — | EP | disclosed |
| CN-103391945-A | Isoxazolidine derivatives | CHIESI FARMA SPA | 2013-11-13 | — | — | CN | disclosed |
| EP-2634174-A2 | Nitrogen-containing hetercyclic derivate having 2-imino group and pest control agent including the same | Meiji Seika Pharma Co., Ltd. (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2633756-A1 | Pest control composition including novel iminopyridine derivate | Meiji Seika Pharma Co., Ltd. (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1574503-B1 | 2,4-Diamino-1,3,5-triazine derivative | HAMARI CHEMICALS LTD (JP) | 2013-03-13 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-101273016-B | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA NV | 2013-01-02 | — | — | CN | disclosed |
| WO-2012163959-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2012-12-06 | — | — | WO | disclosed |
| EP-2507230-A1 | INSECTICIDAL COMPOUNDS BASED ON ISOXAZOLINE DERIVATIVES | Syngenta Participations AG (CH) | 2012-10-10 | — | — | EP | disclosed |
| US-20120234316-A1 | ISOXAZOLIDINE DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-09-20 | — | — | US | disclosed |
| WO-2012120262-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | LARSSON PIA (SE) | 2012-09-13 | — | — | WO | disclosed |
| CN-102498095-A | Indoline derivatives | TOKYO INST TECH | 2012-06-13 | — | — | CN | disclosed |
| US-20120040993-A1 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2012-02-16 | — | — | US | disclosed |
| EP-2394990-A1 | INDOLINE DERIVATIVES | Kyoto University (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294850-A1 | INDOLINE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-12-01 | — | — | US | disclosed |
| WO-2011067272-A1 | INSECTICIDAL COMPOUNDS BASED ON ISOXAZOLINE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | disclosed |
| US-7915292-B2 | 2-{benzyl-[(6-methyl-2-phenyl-quinolin-3-yl)-phenyl-methyl]-amino}-N-(4-methyl-piperazin-1-yl)-acetamide; tuberculosis; antimycobacterial drugs; a tertiary nitrogen atom in the alpha position in the side chain attached to the 3-position of the quinoline nucleus to get fewer enantiomers possible | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| EP-2233493-A1 | Macrolides | Pfizer Products Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010086860-A2 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2010-08-05 | — | — | WO | disclosed |
| CN-101784278-A | Purin derivatives for use in the treatment of FAB-related diseases | BOEHRINGER INGELHEIM INT | 2010-07-21 | — | — | CN | disclosed |
| EP-2190434-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2010-06-02 | — | — | EP | disclosed |
| EP-1836211-B1 | MACROLIDES | PFIZER PROD INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-7622469-B2 | 2,4-diamino-1,3,5-triazine derivatives | HAMARI CHEMICALS, LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| CN-100551916-C | New 2,4-diamino-1,3,5-triazines derivative | HAMARI CHEMICALS LTD (JP) | 2009-10-21 | — | — | CN | disclosed |
| US-7595317-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| EP-2091929-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | The European Molecular Biology Laboratory (DE) | 2009-08-26 | — | — | EP | disclosed |
| CN-101421257-A | Agents that disrupt cellular replication and their use in inhibiting pathological conditions | EUROPEAN MOLECULAR BIOLOGY LAB EMBL (DE) | 2009-04-29 | — | — | CN | disclosed |
| US-7511144-B2 | Reverse hydroxamic acid derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| WO-2009024542-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-26 | — | — | WO | disclosed |
| EP-1431285-B1 | REVERSE HYDROXAMIC ACID DERIVATIVES | KAKEN PHARMA CO LTD (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-7462600-B2 | Macrolides | PFIZER INC (US) | 2008-12-09 | — | — | US | disclosed |
| CN-101273016-A | Antibacterial quinoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | CN | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| US-20080182855-A1 | Antibacterial Quinoline Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-31 | — | — | US | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| EP-1912948-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-23 | — | — | EP | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| CN-101120011-A | Macrolides | PFIZER PROD INC (US) | 2008-02-06 | — | — | CN | disclosed |
| US-7294624-B2 | Osteoporosis; antiarthritic agents | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| WO-2007115805-A2 | AURORA KINASE INHIBITORS | EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) (DE) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007113005-A2 | 2-SUBSTITUTED 3-AMINOSULFONYL-THIOPHENE DERIVATIVES AS AURORA KINASE INHIBITORS | EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) (DE) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007107352-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2007-09-27 | — | — | WO | disclosed |
| EP-1830858-A2 | 3, 6-BICYCLOLIDES | Enanta Pharmaceuticals, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | DUAN JINGWU | 2007-07-19 | — | — | US | disclosed |
| WO-2007014885-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-08 | — | — | WO | disclosed |
| US-20060154928-A1 | Novel 2,4-diamino-1,3,5-triazine derivative | HAMARI CHEMICALS, LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| US-20060135447-A1 | Macrolides | CHUPAK LOUIS S | 2006-06-22 | — | — | US | disclosed |
| WO-2006063039-A2 | 3, 6-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1726199-A | Novel 2,4-diamino-1,3,5-triazine derivative | HAMARI CHEMICALS LTD (JP) | 2006-01-25 | — | — | CN | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1574503-A1 | NOVEL 2,4-DIAMINO-1,3,5-TRIAZINE DERIVATIVE | Hamari Chemicals Co., Ltd. (JP) | 2005-09-14 | — | — | EP | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | STUDOR S.A. (LU) | 2004-12-02 | — | — | US | disclosed |
| EP-1431285-A1 | REVERSE HYDROXAMIC ACID DERIVATIVES | Kaken Pharmaceutical Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003053941-A2 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003040103-A1 | β-SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-15 | — | — | WO | disclosed |
| US-6040449-A | USEFUL FOR FORMING FLUORINE CONTAINING 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES, USEFUL AS ANTAGONIST FOR MUSCARINIC M3 RECEPTORS AND LESS SIDE EFFECT | BANYU PHARMACEUTICAL CO LTD (JP) | 2000-03-21 | — | — | US | disclosed |
| US-5948792-A | POTENT AND SELECTIVE ANTAGONISTS FOR MUSCARINIC M.SUB.3 RECEPTORS WITH LITTLE SIDE EFFECTS. | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-07 | — | — | US | disclosed |
| CN-1226888-A | Fluorinated 1,4-disubstituted piperidine derivatives | BANYU PHARMA CO LTD (JP) | 1999-08-25 | — | — | CN | disclosed |
| EP-0930298-A1 | FLUORINATED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-21 | — | — | EP | disclosed |
| CN-1206423-A | Peptide derivatives of Dolastatin 15 and their use | BASF AG (DE) | 1999-01-27 | — | — | CN | disclosed |
| EP-0247381-B1 | 5-FLUROROURACIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-04 | — | — | EP | disclosed |
| US-5047521-A | Anticarcinogenic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
| US-4698329-A | HYPOTENSIVE AGENTS | SANKYO COMPANY, LIMITED (JP) | 1987-10-06 | — | — | US | disclosed |
| EP-0152255-A2 | New renin-inhibitory peptides and their use | SANKYO COMPANY LIMITED (JP) | 1985-08-21 | — | — | EP | disclosed |
| EP-0152255-A2 | New renin-inhibitory peptides and their use | SANKYO COMPANY LIMITED (JP) | 1985-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (27 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315839-A1 | PEST CONTROL COMPOSITION INCLUDING NOVEL IMINOPYRIDINE DERIVATIVE | API5, DDT, INTS9 | MAPT 4300/4885KDM4E 258/4885POLB 3965/4885 |
| US-20150057257-A1 | ISOXAZOLIDINE DERIVATIVES | IL5, TSLP, SERPINA6 | MAPT 4471/4885KDM4E 4228/4885POLB 1045/4885 |
| US-20220000877-A1 | AQUEOUS COMPOSITION, IN PARTICULAR FOR TREATING MUCOSA AND/OR WOUNDS | MUC1, DSG1, AQP3 | MAPT 716/4885KDM4E 4117/4885POLB 375/4885 |
| US-20120234316-A1 | ISOXAZOLIDINE DERIVATIVES | IL5, TSLP, SERPINA6 | MAPT 4471/4885KDM4E 4228/4885POLB 1045/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MAPT 4117/4885KDM4E 4854/4885POLB 1637/4885 |
| US-20120040993-A1 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | GSR, GRIN1, GRIN2A | MAPT 1195/4885KDM4E 3218/4885POLB 2564/4885 |
| US-20080182855-A1 | Antibacterial Quinoline Derivatives | NDUFB5, NQO2, MT-ND5 | MAPT 135/4885KDM4E 4086/4885POLB 181/4885 |
| US-20060135447-A1 | Macrolides | LCAT, NOP2, HDAC6 | MAPT 1800/4885KDM4E 3426/4885POLB 1605/4885 |
| US-20160340349-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | PLPBP, PDXK, PNPO | MAPT 2709/4885KDM4E 1409/4885POLB 3223/4885 |
| US-10000476-B2 | Pyridone derivative, pharmaceutical containing the same and methods of use thereof | PNPO, PDXK, PLPBP | MAPT 3357/4885KDM4E 1371/4885POLB 3715/4885 |
| US-20160168540-A1 | COMPOSITION FOR MAINTAINING PLATELET FUNCTION | PF4, F2, PFKP | MAPT 4563/4885KDM4E 4157/4885POLB 4128/4885 |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | TNF, MMP9, MMP3 | MAPT 2040/4885KDM4E 2397/4885POLB 1914/4885 |
| US-20110294850-A1 | INDOLINE DERIVATIVES | BCHE, ACHE, INMT | MAPT 2067/4885KDM4E 2207/4885POLB 4025/4885 |
| US-20150166506-A1 | PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | PLPBP, PDXK, PNPO | MAPT 2709/4885KDM4E 1409/4885POLB 3223/4885 |
| US-20100280049-A1 | ANTAGONISTS OF PGD2 RECEPTORS | PTGDR2, PTGDR, LTB4R2 | MAPT 4781/4885KDM4E 4709/4885POLB 4359/4885 |
| US-20180066010-A1 | ISOXAZOLIDINE DERIVATIVES | IL5, TSLP, SERPINA6 | MAPT 4471/4885KDM4E 4228/4885POLB 1045/4885 |
| US-10280193-B2 | Isoxazolidine derivatives | IL5, TSLP, SERPINA6 | MAPT 4471/4885KDM4E 4228/4885POLB 1045/4885 |
| US-20230165252-A1 | ACTIVE COMPOUND COMBINATIONS | CYP51A1, ERG28, BROX | MAPT 3157/4885KDM4E 978/4885POLB 2728/4885 |
| US-10349655-B2 | Pest control composition including novel iminopyridine derivative | API5, DDT, INTS9 | MAPT 4300/4885KDM4E 258/4885POLB 3965/4885 |
| US-20060154928-A1 | Novel 2,4-diamino-1,3,5-triazine derivative | DAZAP1, DCUN1D5, TLR5 | MAPT 3174/4885KDM4E 2587/4885POLB 2845/4885 |
| US-20040242928-A1 | Tumor necrosis factor converting enzyme inhibitor; antiarthritic agents; lupus; Crohn's disease; multiple sclerosis; antidiabetic agents; infections;; asthma; skin disorders; anemia | TNF, RNASE1, IFNAR1 | MAPT 4413/4885KDM4E 2703/4885POLB 1864/4885 |
| US-20160165888-A1 | PEST CONTROL COMPOSITION INCLUDING NOVEL IMINOPYRIDINE DERIVATIVE | API5, DDT, INTS9 | MAPT 4300/4885KDM4E 258/4885POLB 3965/4885 |
| US-20150005347-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 2-IMINO GROUP AND PEST CONTROL AGENT INCLUDING THE SAME | CBR1, CBR3, NIT2 | MAPT 4773/4885KDM4E 1283/4885POLB 3786/4885 |
| US-20230054449-A1 | PYRIDAZINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | PNPO, TPMT, BLVRB | MAPT 928/4885KDM4E 1410/4885POLB 3241/4885 |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | PNP, ENTPD5, NUDT14 | MAPT 4548/4885KDM4E 3292/4885POLB 349/4885 |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | PNP, PURB, NUDT14 | MAPT 4630/4885KDM4E 2873/4885POLB 524/4885 |
| US-20210401848-A1 | AQUEOUS COMPOSITION, IN PARTICULAR FOR TREATING MUCOSA AND/OR WOUNDS | DSP, DSG1, MUC1 | MAPT 989/4885KDM4E 3874/4885POLB 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.